Saudi Evidence Infrastructure

Building the Saudi
Evidence Layer
for Rare Diseases.

Momaiza is building a Saudi-focused evidence infrastructure that connects clinical research, natural history evidence, real-world evidence, data provenance, research intelligence and future evidence technologies.

Momaiza
Natural History
Real-World Evidence
Clinical Research
Data & Analytics
Evidence & Regulatory
Why Momaiza

Saudi Arabia already has the ingredients. The missing layer is connected evidence.

Saudi Arabia is rapidly expanding genomics, biotechnology and clinical research capabilities. Momaiza is designed to connect these capabilities into evidence that can support research, development, regulatory strategy and better healthcare decisions.

63,000
genomic samples reported by the Saudi Genome Program
7,500+
genetic variants documented
140+
scientific publications reported through the program
83%
growth in SFDA clinical-trial applications for advanced therapies and biotechnology products in 2025
Sources: Saudi Vision 2030 / Saudi Genome Program / SFDA. Figures and descriptions reflect the referenced public sources and are not Momaiza-owned datasets.
Saudi Market Intelligence

The evidence gap is real.

Recent Saudi research highlights gaps in rare-disease evidence, registries, natural-history data, research capacity and evidence generation. These gaps create a strategic opportunity for infrastructure built around high-quality local evidence.

Laboratory and biotechnology research 2025

Rare-disease ecosystem challenges in Saudi Arabia

A multi-stakeholder Saudi workshop identified delayed diagnosis, limited awareness, insufficient screening, regulatory barriers, financial constraints and the need for stronger national registry and research infrastructure.

Read research →
Clinical research laboratory 2025

Local evidence gaps for rare-disease therapies

A Saudi Delphi consensus highlighted limited local epidemiological data, insufficient natural-history data, fragmented data systems and challenges in generating RWE for rare-disease decision making.

Read research →
Medical science and genomics Vision 2030

Genomics as national health infrastructure

The Saudi Genome Program is building national genomic infrastructure to support diagnosis, prevention, research and precision healthcare.

Read source →
Core Strategic Concept

Saudi Rare Disease Evidence Sovereign Layer

طبقة الأدلة السيادية للأمراض النادرة في السعودية

Momaiza is designed to evolve beyond a traditional research-services model toward an evidence infrastructure layer: generating, structuring, governing and connecting Saudi-specific rare-disease evidence for research, healthcare, life sciences and regulatory decision making.

01

Natural History Evidence

Structured longitudinal understanding of disease progression, patient journeys, outcomes and real-world care.

02

Real-World Evidence

Research-ready evidence generated from real-world clinical environments under appropriate governance and methodological standards.

03

Evidence Provenance

Traceable evidence lineage showing where data originated, how it was transformed and how conclusions were generated.

04

Future Evidence Intelligence

A future layer for evidence analytics, simulation and decision support built on accumulated high-quality evidence.

Why Saudi Arabia

A national transformation is creating demand for better evidence.

Genomics, biotechnology, advanced therapies and clinical research are moving forward simultaneously. Evidence infrastructure becomes increasingly valuable as these systems mature.

Genomics & Precision Health

The Saudi Genome Program is developing national genomic infrastructure and aims to enable researchers to use genomic data, study genetic variants and strengthen diagnosis and prevention.

Genomics Precision Medicine Genetic Disease

Biotechnology & Advanced Therapies

Saudi Arabia's National Biotechnology Strategy targets major growth in genomics, biomanufacturing and medical innovation, creating a stronger environment for clinical research and evidence generation.

Biotechnology Clinical Trials Advanced Therapies
Defensibility

The difficult part is not building another website. It is building trusted evidence infrastructure.

A Saudi evidence layer becomes harder to replicate as methodology, institutional relationships, disease knowledge, longitudinal evidence and governance capabilities compound over time.

01

Local Ecosystem

Saudi-specific research relationships, clinical networks and understanding of the local healthcare environment.

02

Evidence Depth

Natural-history studies and longitudinal evidence become more valuable as disease-specific knowledge accumulates.

03

Governance

Evidence infrastructure must be designed around privacy, consent, data governance, provenance and appropriate access.

04

Regulatory Relevance

Evidence can be structured to support regulatory, HTA and market-access needs while remaining subject to applicable requirements.

Two-Sided Demand

One evidence layer. Multiple stakeholders who need it.

Life Sciences

Global & Local Life-Sciences Companies

Companies developing or entering Saudi Arabia with rare-disease and advanced therapies need better understanding of the local patient population, disease burden, care pathways, outcomes and evidence environment.

Pharma Biotech Rare Disease Market Access
Saudi Healthcare Ecosystem

Healthcare, Research & Policy Stakeholders

Healthcare systems, researchers and policy stakeholders need stronger local evidence to understand disease burden, evaluate interventions, improve research design and support evidence-informed decisions.

Healthcare Research HTA Evidence
Investment Thesis

From research services to a compounding evidence asset.

The long-term ambition is not simply to sell projects. It is to build an evidence infrastructure in which every study, registry and validated evidence asset increases the capability of the next one.

01

High Barrier to Entry

Deep local context, research relationships, evidence methodology and governance capabilities create a barrier that a generic CRO cannot easily reproduce.

02

Compounding Evidence

Each validated natural-history study, registry and evidence asset can improve future studies, analytics and disease understanding.

03

Multiple Revenue Layers

Custom studies can create near-term revenue while evidence access, analytics, regulatory packages and future platform capabilities create additional long-term revenue streams.

04

Strategic Saudi Positioning

Momaiza is designed around a market where genomics, biotechnology, advanced therapies and clinical research are becoming national priorities.

Revenue Engine

Start with services. Build toward infrastructure.

01

Custom Evidence Studies

Natural-history studies, registries, retrospective research, prospective evidence generation and RWE projects.

02

Evidence & Data Access

Future governed access to appropriately de-identified, consented and validated evidence assets under defined licensing models.

03

Analytics & Intelligence

Evidence synthesis, RWE analytics, research intelligence and decision-support outputs.

04

Regulatory Evidence Packages

Structured evidence packages designed to support regulatory and market-access discussions, subject to applicable requirements.

05

Evidence Licensing

A future model for controlled licensing of evidence assets, methodologies and derived intelligence.

06

Saudi TwinTrials

A future concept for evidence simulation and trial-planning capabilities built on accumulated Saudi-specific evidence.

Proposed Framework

Momaiza Evidence Passport

A proposed framework for documenting the provenance, quality, methodology and evidence status of research assets across their lifecycle.

The Evidence Passport is a proposed Momaiza framework. It is not an official SFDA certification or regulatory designation.

01 SOURCE
02 COLLECT
03 CLEAN
04 ANALYSE
05 EVIDENCE
Strategic Positioning

We are not building another CRO.

Momaiza can start with CRO-like evidence services, but the strategic direction is infrastructure: evidence assets, governance, analytics and reusable knowledge.

Dimension
Traditional CRO
Momaiza
Core model
Project delivery
Evidence infrastructure + services
Data value
Primarily project-specific
Designed to compound across studies
Local evidence
Depends on client/project
Saudi-focused evidence layer
Long-term asset
Expertise and delivery capacity
Evidence, provenance, methodology and intelligence
Evidence Services

Research capabilities that can grow into infrastructure.

Momaiza begins where customers have immediate evidence needs, while building the methodological and operational foundation for the long-term platform.

01

Natural History & Registries

Disease characterization, longitudinal patient journeys, registry design and natural-history evidence generation.

02

Real-World Evidence

Research using real-world clinical data to answer effectiveness, safety, utilization and outcome questions.

03

Clinical Research Intelligence

Research landscape analysis, clinical-trial intelligence, evidence mapping and strategic research support.

04

Data & Evidence Analytics

Statistical analysis, evidence synthesis, research datasets and analytical outputs for decision making.

05

Regulatory Evidence Packages

Structured evidence summaries and analytical packages designed to support regulatory and market-access workflows.

06

Future Evidence Licensing

Future controlled access to validated evidence assets and derived intelligence under appropriate governance.

Momaiza Academy

Building the people behind better evidence.

A fully online professional learning arm focused on practical competencies in clinical research, research data and evidence generation.

Practical Clinical Research Skills

The Academy is designed to connect theory with the practical skills researchers need to produce credible, reproducible and decision-useful evidence.

Clinical Research
GCP
Research Methodology
Clinical Data
R for Researchers
Real-World Evidence
Evidence Generation
Scientific Writing
Saudi Clinical Research Explore clinical-trial growth, research capacity and the evolving Saudi evidence environment.
Rare Diseases Learn from current research on diagnostic delays, evidence gaps, registries and orphan-drug access in Saudi Arabia.
Genomics & Biotechnology Understand how genomics and biotechnology are becoming strategic pillars of Saudi healthcare transformation.
Evidence & RWE Build practical knowledge in evidence generation, real-world data and research analytics.
Nievein Ahmed — Founder of Momaiza

Nievein Ahmed

Medical Laboratory Scientist · Clinical Research Professional

Master’s in Clinical Research from Germany

Founder

Built from laboratory science, clinical research and a belief in better evidence.

Momaiza was founded by Nievein Ahmed, a Medical Laboratory Scientist with a Master's degree in Clinical Research from Germany. Her background combines laboratory science, clinical research and evidence-focused academic training, with an international perspective on healthcare and research.

My background combines Medical Laboratory Science with a Master's degree in Clinical Research from Germany. This academic and professional journey sits at the intersection of laboratory science, clinical research, data and evidence, shaping how I think about data quality, research methodology and the distance between scientific knowledge and decisions that affect patients.

Saudi Arabia was chosen deliberately. The Kingdom's investment in genomics, biotechnology, healthcare transformation and clinical research creates an environment where high-quality local evidence can become strategically important.

Momaiza's ambition is to help build the evidence infrastructure Saudi Arabia needs to become a stronger global center for rare-disease and advanced-therapy evidence.
Future Vision

A roadmap from expertise to infrastructure.

PHASE 01

Evidence Services

Build expertise, customer relationships, methodologies and initial revenue through evidence projects.

PHASE 02

Registries & Natural History

Build disease-specific evidence capabilities and longitudinal research assets.

PHASE 03

Evidence Platform

Connect evidence provenance, analytics, governance and controlled access into a scalable infrastructure.

PHASE 04

Saudi TwinTrials

Future concept for simulation, trial planning and evidence intelligence using accumulated Saudi-specific evidence.

Strategic Ecosystem

Designed to connect the Saudi healthcare, research and life-sciences ecosystem.

Momaiza is designed to collaborate through appropriate future partnerships with healthcare institutions, research centers, universities, genomics initiatives, regulators, biotechnology companies, pharmaceutical companies and patient organisations.

Research Hospitals Universities Genomics Initiatives Regulatory Ecosystem Biotech Pharma Patient Organisations
Contact Momaiza

Let’s have a conversation.

If you are exploring clinical research, rare-disease evidence, real-world evidence, Saudi market entry or strategic evidence partnerships, we would like to hear from you.